skinny.

Latest / Eyewire News: The Podcast

Lumithera CEO Discusses FDA Authorization for Veleda for Dry AMD

The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.